Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
NUTLEY, N.J., Sept. 10, 2022 /PRNewswire/ -- Eisai announced today results from a post-hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301, and Study 304) evaluating the efficacy of eribulin mesylate (marketed as HALAVEN®) versus other chemotherapies (Treatment of Physician's Choice [TPC], capecitabine, and vinorelbine, respectively) in patients living with metastatic breast cancer (mBC) whose tumors have low or no HER2 expression. These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022.
WOODCLIFF LAKE, N.J., May 18, 2021 /PRNewswire/ -- Eisai today announced results from a real-world study assessing treatment patterns and clinical outcomes with HALAVEN® (eribulin mesylate) injection as a third-line therapy or greater in patients with metastatic breast cancer (mBC), including the triple-negative breast cancer (TNBC) subtype. These data were recently published in Advances in Therapy.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in the phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven® (generic name: eribulin mesylate, “eribulin”) were presented (abstract number: 346P) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
WOODCLIFF LAKE, N.J., May 13, 2020 /PRNewswire/ -- Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology's ASCO20 Virtual Scientific Program from May 29-31. Data from ongoing trials on the investigational combination of lenvatinib plus pembrolizumab will be featured, including data from Study 111/KEYNOTE-146 trial in two cohorts: a virtual oral presentation from the mccRCC cohort (Abstract #5008) and a virtual poster from the advanced or recurrent endometrial cancer cohort (Abstract #6083).
FDA Confirms Paragraph IV Patent Challenge of Halaven 201532 (Eribulin Mesylate 1 mg/2 mL ) Injection
Japan headquartered Eisai Co., Ltd. has announced that it has launched the in-house developed anticancer agent Halaven® (generic name: eribulin mesylate) in China.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched thenin-house developed anticancer agent Halaven® (product name in China: 海乐卫®, generic name: eribulinnmesylate) in China.